These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. Lima M An Bras Dermatol; 2015; 90(5):687-706. PubMed ID: 26560215 [TBL] [Abstract][Full Text] [Related]
25. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Terhorst D; Mestel DS; Humme D; Sterry W; Beyer M Br J Dermatol; 2012 Jun; 166(6):1295-300. PubMed ID: 22356095 [TBL] [Abstract][Full Text] [Related]
27. Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management. Wilcox RA Am J Hematol; 2015 Jan; 90(1):73-6. PubMed ID: 25535037 [TBL] [Abstract][Full Text] [Related]
28. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. Bonnekoh B; Schulz M; Franke I; Gollnick H J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303 [TBL] [Abstract][Full Text] [Related]
29. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab. Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675 [No Abstract] [Full Text] [Related]
30. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. Hallermann C; Niermann C; Fischer RJ; Schulze HJ Acta Derm Venereol; 2011 Sep; 91(5):521-5. PubMed ID: 21547335 [TBL] [Abstract][Full Text] [Related]
31. [Lymphomas of the skin]. Nagatani T; Baba N; Nakajima H Gan To Kagaku Ryoho; 1993 Aug; 20(10):1308-13. PubMed ID: 7688500 [TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Sokol L; Naghashpour M; Glass LF Cancer Control; 2012 Jul; 19(3):236-44. PubMed ID: 22710899 [TBL] [Abstract][Full Text] [Related]
36. [Primary cutaneous B-cell lymphomas: study of 22 cases]. Martín Carrasco P; Morillo Andújar M; Pérez Ruiz C; de Zulueta Dorado T; Cabrera Pérez R; Conejo-Mir J Med Clin (Barc); 2016 Sep; 147(5):207-210. PubMed ID: 27427313 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Pulini S; Rupoli S; Goteri G; Pimpinelli N; Alterini R; Bettacchi A; Mulattieri S; Picardi P; Tassetti A; Scortechini AR; Fioritoni G; Leoni P Eur J Haematol; 2009 Mar; 82(3):184-93. PubMed ID: 19215609 [TBL] [Abstract][Full Text] [Related]
38. [Cutaneous large B-cell leg-type lymphoma occurring on a leg burn]. Meziane M; Hesse S; Chetaille B; Bien-Aimée A; Grob JJ; Richard MA Ann Dermatol Venereol; 2009 Nov; 136(11):791-4. PubMed ID: 19917431 [TBL] [Abstract][Full Text] [Related]
39. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Wilcox RA Am J Hematol; 2018 Nov; 93(11):1427-1430. PubMed ID: 30039522 [TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. Zinzani PL; Quaglino P; Pimpinelli N; Berti E; Baliva G; Rupoli S; Martelli M; Alaibac M; Borroni G; Chimenti S; Alterini R; Alinari L; Fierro MT; Cappello N; Pileri A; Soligo D; Paulli M; Pileri S; Santucci M; Bernengo MG; J Clin Oncol; 2006 Mar; 24(9):1376-82. PubMed ID: 16492713 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]